McMMAF

SKU: orb1308052

Description

McMMAF is a maleimidocaproyl-linked derivative of the cytotoxic agent MMAF, designed for the facile preparation of antibody-drug conjugates (ADCs). This prodrug enables targeted delivery of the potent tubulin inhibitor for research in oncology, supporting both in vitro cytotoxicity studies and in vivo efficacy models of ADC therapeutics.

Research Area

Cell Biology, Signal Transduction

Key Properties

• CAS Number: 863971-19-1
• MW: 925.16
• Purity: 99.65% (May vary between batches)
• Formula: C₄₉H₇₆N₆O₁₁
• SMILES: [C@H]([C@H](C(N[C@@H](CC1=CC=CC=C1)C(O)=O)=O)C)(OC)[C@]2(N(C(C[C@H]([C@@H](N(C([C@@H](NC([C@@H](N(C(CCCCCN3C(=O)C=CC3=O)=O)C)[C@@H](C)C)=O)C(C)C)=O)C)[C@H](CC)C)OC)=O)CCC2)[H]
• Target: Microtubule Associated,Apoptosis,Drug-Linker Conjugates for ADC
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:5 mg/mL (5.4 mM);DMSO:100 mg/mL (108.09 mM)

Bioactivity

• In Vitro:
  MMAF induces potent antitumor effects when conjugated via protease cleavable linkers to a monoclonal antibody targeting internalizing, tumor-specific cell surface antigens. MMAF is a new auristatin derivative with a charged C-terminal phenylalanine that attenuates its cytotoxic activity compared to its uncharged counterpart, Monomethyl auristatin E (MMAE). It cannot be used as a drug itself because MMAF is highly toxic. The linker to the monoclonal antibody is stable in extracellular fluid but is cleaved by cathepsin once the conjugate has entered a tumor cell, thus activating the anti-mitotic mechanism.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

DrugLinkerConjugatesforADC, DrugLinker Conjugates for ADC, Drug-Linker Conjugates for ADC, Auristatin, inhibit, Microtubule Associated, MicrotubuleAssociated, Inhibitor, McMMAF, Maleimidocaproyl monomethylauristatin F, tubulin polymerization

Compound Identifiers

PubChem CID

56949327